Dr Hannah McManus looks ahead to the release of new data from phase 3 clinical trials that will inform multidisciplinary ...

Men diagnosed at screening aged 50 years projected to have 16 percent chance that cancer would not have been detected within 15 years.

Follow-up overall survival, months, median (range) 96 (15-120) Follow-up PSA to recurrence or death, months, median (range) 55 (11-111) Follow-up PSA patients alive and recurrence-free, months, median ...

In tandem with September’s Prostate Cancer Awareness Month, Cleveland Diagnostics is kicking off a campaign to boost awareness of and education around screening tests for the disease. The flagship ...

This study examined changes in prostate disease screening (prostatic-specific antigen [PSA] testing), prostate biopsy testing, and prostate cancer diagnoses during the COVID-19 pandemic through ...

The National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-has published a new book explaining ...

Former president Joe Biden’s newly diagnosed prostate cancer, an aggressive form that has spread to his bones, has renewed the debate about who should receive annual screenings for signs of the ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a medicine that is used to treat prostate cancer in adults. Pluvicto may be used to treat PSMA-positive prostate cancer that has spread to other ...